Inotropes and β-blockers: Is there a need for new guidelines?

Journal of Cardiac Failure

Volumn 7, Issue 2 PART II, 2001, Pages 8-12

  Bristow, Michael R ^a   Shakar, Simon F ^a   Linseman, Jennifer V ^a   Lowes, Brian D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Contractility; Heart failure; Inotropes; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOTONIC AGENT; PHOSPHODIESTERASE INHIBITOR;

CONGESTIVE HEART FAILURE; DRUG COMBINATION; DRUG EFFECT; HEART CONTRACTION; HUMAN; PHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; TIME; TREATMENT OUTCOME; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; CARDIOTONIC AGENTS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; PHOSPHODIESTERASE INHIBITORS; PRACTICE GUIDELINES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0035376795     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2001.26655     Document Type: Article

References (22)

1. Eichhorn EJ, Bristow MR: Medical therapy can improve the biologic properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 1996;94:2285-2296
2. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533
3. Bristow MR: Management of heart failure. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease. A textbook of cardiovascular medicine. 6th ed. Philadelphia: Saunders, 2001, pp 635-651
4. Lowes BD, Higginbotham M, Petrovich L, DeWood MA, Weber K, Greenberg MA, Rahko PS, Dec W, LeJemtel T, Roden R, Schleman MM, Robertson AD, Gorczynski RJ, Bristow MR: Low-dose enoximone improves exercise capacity in chronic heart failure. J Am Coll Cardiol 2000;36:501-508
5. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig hears. Circ Res 1995;77:107-113
6. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999;96:7059-7064
7. 1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000;32:817-830
8. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000; 101:1707-1714
9. Luo W, Grupp IL, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG: Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 1994;75:401-409
10. Minamisawa S, Hoshijima M, Chu G, Marione ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR: Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999;98:313-322
11. Freeman K, Lerman J, Kranias EG, Bohlmayer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA: Alterations in cardiac adrenergic signaling and calcium cycling differentally affect the progression of cardiomyopathy. J Clin Invest 2001;107:967-974
12. Rockman HA, Chien KR, Choi D-J, Iarccarino G, Hunter JJ, Ross J Jr, Lefkowitz RJ, Koch WJ: Expression of a β-adrenergic receptor kinase I inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998;95:7000-7005
13. Delmonte F, Harding SE, Rosenzweig A, Gwathmey JK, Hajjar RJ: Improvement in contractile function in isolated failing human cardiac myocytes by gene transfer of antisense phospholamban (abstr). Circulation 2000; 102(suppl II):II-720
14. Bristow MR, Gilbert EM, Lowes BD, Minobe W, Shakar S, Quaife RA, Abraham WT: Changes in myocardial gene expression associated with β-blocker-related improvement in ventricular systolic function (abstr). Circulation 1997;96 (suppl):I-92
15. 2+ ATPase (abstr). J Am Coll Cardiol 1999;33(suppl A):216A
16. Lowes BD, Simon MA, Tsekova TO, Bristow MR: Inotropes in the β-blocker era (abstr). Clin Cardiol 2000;23(suppl 3):11-16
17. Böhm M, Deutsch HJ, Hartmann D, LaRosée K, Stäblein A: Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997;30:992-996
18. Tsvetkova TO, Farber DJ, Abraham WT, Kelley P, Eichhorn E, Gilbert EM, Robertson AD, Lindenfeld J, Wolfel EE, Zisman L, Bristow MR, Lowes BD: Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol (abstr). J Card Fail 1998;4(suppl 1):36
19. Metra M, Nodari S, Boldi E, Bontempi L, Chizzola G, Bordanali T, Vizzardi E, Dei Cas L: Different responses to inotropic agents after long term β-blockade with either metoprolol or carvedilol in patients with chronic heart failure (abstr). Eur J Heart Fail 2000;2:57
20. iα(-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 1996;51:127-132
21. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Ferguson DA, Bristow MR: Combined oral positive inotropic and beta-blocker therapy for the treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-1340
22. Yatani A, Codina J, Imoto Y, Reeves JP, Birnbaumer L, Brown AM: A G protein directly regulates mammalian cardiac calcium channels. Science 1987;238:1288-1292